AstraZeneca's First Data on Head and Neck Cancer Drug Looks Unexciting -- Market Talk

Dow Jones06-01

1056 GMT - AstraZeneca's initial data on an experimental drug for head and neck cancer is unlikely to build excitement, though this isn't in focus for the U.K. drugmaker, Jefferies analysts say in a note. A first glance at data for AstraZeneca's volrustomig as a first-line treatment for head and neck squamous cell carcinoma shows the median progression-free survival is below that of rival drugs including Merck's blockbuster Keytruda, the analysts say. The underwhelming data have no impact on Jefferies' investment thesis, given that this isn't a core drug, the analysts say. Volrustomig, which is currently in phase 2 studies, is a so-called bispecific antibody designed to target two proteins simultaneously and release the body's immune system to attack cancer. Shares fall 1.1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 01, 2026 06:56 ET (10:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640495559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640495559","market":"other","top_or_hot":-1,"title":"AstraZeneca's First Data on Head and Neck Cancer Drug Looks Unexciting -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1056 GMT - AstraZeneca's initial data on an experimental drug for head and neck cancer is unlikely to build excitement, though this isn't in focus for the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker, Jefferies analysts say in a note. A first glance at data for AstraZeneca's volrustomig as a first-line treatment for head and neck squamous cell carcinoma shows the median progression-free survival is below that of rival drugs including Merck's blockbuster Keytruda, the analysts say. The underwhelming data have no impact on Jefferies' investment thesis, given that this isn't a core drug, the analysts say. Volrustomig, which is currently in phase 2 studies, is a so-called bispecific antibody designed to target two proteins simultaneously and release the body's immune system to attack cancer. Shares fall 1.1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 06:56 ET (10:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca's First Data on Head and Neck Cancer Drug Looks Unexciting -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca's First Data on Head and Neck Cancer Drug Looks Unexciting -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-01 18:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1056 GMT - AstraZeneca's initial data on an experimental drug for head and neck cancer is unlikely to build excitement, though this isn't in focus for the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker, Jefferies analysts say in a note. A first glance at data for AstraZeneca's volrustomig as a first-line treatment for head and neck squamous cell carcinoma shows the median progression-free survival is below that of rival drugs including Merck's blockbuster Keytruda, the analysts say. The underwhelming data have no impact on Jefferies' investment thesis, given that this isn't a core drug, the analysts say. Volrustomig, which is currently in phase 2 studies, is a so-called bispecific antibody designed to target two proteins simultaneously and release the body's immune system to attack cancer. Shares fall 1.1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 06:56 ET (10:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443549.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640495559","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640495559","pubTimestamp":1780311360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1056 GMT - AstraZeneca's initial data on an experimental drug for head and neck cancer is unlikely to build excitement, though this isn't in focus for the U.K. drugmaker, Jefferies analysts say in a note. A first glance at data for AstraZeneca's volrustomig as a first-line treatment for head and neck squamous cell carcinoma shows the median progression-free survival is below that of rival drugs including Merck's blockbuster Keytruda, the analysts say. The underwhelming data have no impact on Jefferies' investment thesis, given that this isn't a core drug, the analysts say. Volrustomig, which is currently in phase 2 studies, is a so-called bispecific antibody designed to target two proteins simultaneously and release the body's immune system to attack cancer. Shares fall 1.1%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4585":"ETF&股票定投概念","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","AZNH":"ASTRAZENECA PLC ADRhedged","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","BK4588":"碎股","AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD"},"translate_title":"阿斯利康头颈癌药物的第一个数据看起来并不令人兴奋——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"AZNH":0.6},"content_text":"1056 GMT - AstraZeneca's initial data on an experimental drug for head and neck cancer is unlikely to build excitement, though this isn't in focus for the U.K. drugmaker, Jefferies analysts say in a note. A first glance at data for AstraZeneca's volrustomig as a first-line treatment for head and neck squamous cell carcinoma shows the median progression-free survival is below that of rival drugs including Merck's blockbuster Keytruda, the analysts say. The underwhelming data have no impact on Jefferies' investment thesis, given that this isn't a core drug, the analysts say. Volrustomig, which is currently in phase 2 studies, is a so-called bispecific antibody designed to target two proteins simultaneously and release the body's immune system to attack cancer. Shares fall 1.1%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 06:56 ET (10:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640495559","isCrawlerRequest":true}